Fda clears minimed™ 780g system to enable integration with the instinct sensor, made by abbott, and approves use in type 2 diabetes

Galway, ireland , sept. 2, 2025 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced two u.s. food and drug administration (fda) regulatory milestones that broaden the minimed™ 780g system portfolio: clearance of the smartguard™ algorithm as an interoperable automated glycemic controller (iagc), enabling integration with the instinct sensor, made by abbott, for type 1 diabetes, and approval of the minimed™ 780g system for use in adults 18+ with insulin-requiring type 2 diabetes.
MDT Ratings Summary
MDT Quant Ranking